Der Einmaleffekt von 6,5 Mrd. USD, der größtenteils in die Verbindlichkeiten gebucht wurde, hängt doch mit dem Vergleich im Opiate-Rechtstreit zusammen.
10Q, S. 36 The Company recorded a $6.5 billion liability associated with the Settlement Frameworks and other opioid-related claims and litigation during the three months ended November 30, 2022. The settlement accrual is reflected in the Consolidated Condensed Statement of Earnings within Selling, general and administrative expenses as part of the U.S. Retail Pharmacy segment. The Company recorded $619 million and $5.9 billion of the estimated settlement liability in Accrued expenses and other current liabilities, and Accrued litigation obligations, respectively, in the Consolidated Condensed Balance Sheet.
https://d18rn0p25nwr6d.cloudfront.net/...3-44be-be2a-db702de3792e.pdf |